2013
Can markers of collagen turnover or other biomarkers contribute to the diagnostics of heart failure with normal left ventricular ejection fraction?
MELUZÍN, Jaroslav; Josef TOMANDL; Helena PODROUŽKOVÁ; Zdeňka GREGOROVÁ; Vladimír SOŠKA et al.Základní údaje
Originální název
Can markers of collagen turnover or other biomarkers contribute to the diagnostics of heart failure with normal left ventricular ejection fraction?
Autoři
MELUZÍN, Jaroslav; Josef TOMANDL ORCID; Helena PODROUŽKOVÁ; Zdeňka GREGOROVÁ; Vladimír SOŠKA; Petr DOBŠÁK; Ladislav PECEN a Radka STEPANOVA
Vydání
Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic, Olomouc, Palacký University, 2013, 1213-8118
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.661
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/13:00070610
Organizační jednotka
Lékařská fakulta
UT WoS
Klíčová slova anglicky
echocardiography; heart failure with normal ejection fraction; biomarkers
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 29. 3. 2014 22:25, Ing. Mgr. Věra Pospíšilíková
Anotace
V originále
Aims. Plasma levels of some biomarkers and markers of collagen turnover may reflect myocardial structural abnormalities associated with diastolic dysfunction. The aim of this study was to determine whether these markers could contribute to the diagnostics of heart failure with normal ejection fraction (HFNEF). Methods and Results. 91 patients with exertional dyspnea and normal left ventricular ejection fraction and 20 healthy controls underwent plasma analysis of markers of collagen turnover and other biomarkers, spirometry, and resting and exercise echocardiography. 38 patients with dyspnea had evidence of HFNEF, diagnosed at the early stage. Compared to the remaining patients, those with HFNEF had a significantly higher plasma levels of carboxy-terminal telopeptide of collagen type I (median 4.5 ug/L vs. 3.5 ug/L, P<0.05) and big endothelin (median 1.1 pmol/L vs 0.9 pmol/L, P<0.05). Univariate logistic regression analysis revealed a significant association between HFNEF and the following biomarkers: big endothelin, amino-terminal propeptide of type III procollagen (PIIINP), and matrix metalloproteinase-2 (MMP-2). However, none of these biomarkers independently contributed to the HFNEF diagnostics in a multivariate logistic regression analysis. Conclusion Plasma levels of big endothelin, PIIINP, and MMP-2 were found to be associated with the presence of early diagnosed HFNEF. However, none of these biomarkers contributed independently to current noninvasive HFNEF diagnostics recommended by the European Society of Cardiology guidelines.